BioMarin Pharmaceutical Inc. (BIT:1BMRN)

Italy · Delayed Price · Currency is EUR

45.84

-0.43 (-0.93%)

At close: Dec 5, 2025

-26.63% (1Y)

Market Cap	8.82B
Revenue (ttm)	2.64B
Net Income (ttm)	443.55M
Shares Out	n/a
EPS (ttm)	2.28
PE Ratio	19.88
Forward PE	11.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	17
Open	n/a
Previous Close	46.27
Day's Range	n/a
52-Week Range	43.05 - 67.42
Beta	n/a
RSI	43.75
Earnings Date	Feb 20, 2026

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1996

Employees 3,040

Stock Exchange Borsa Italiana

Ticker Symbol 1BMRN

Full Company Profile

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD Financial Statements

News

There is no news available yet.